Arpeggio Biosciences

We're so proud to announce Kevin Eastwood as Arpeggio's Chief Business Officer and to have worked with the incredible team at Slone Partners. Welcome, Kevin Eastwood! We are truly thrilled to join forces with you.

The CBSA team was thrilled to partner with BioLife for the Mountain West 2024 in Denver!    This day of insightful conversation, educational panel topics, and networking, offered Colorado’s life sciences community a chance to connect and learn from life sciences leaders, including Elyse Blazevich, CBSA President and CEO, as well as some of our members:    Joey Azofeifa, CEO & Co-founder, Arpeggio Biosciences    Mary Stewart, SVP Compliance, Communications, Policy, Foresight Diagnostics   Julie Stiff, Interim Site Head & Sr Director Facilities & Engineering, Boulder Operations, KBI Biopharma    Alexander Fisher, COO & Co-founder, AOA Dx   Greg Tebbe, Sr. Director Global Marketing, Medtronic    Hannah Gordon, PhD, MSCI, Chief Product Officer, Enveda Biosciences    Heather Callender-Potters, EVP & Co-founder, PharmaJet    Hilary Baldwin, VP Regulatory and Clinical Affairs, Eximis Surgical    Jeffrey A. Jeddeloh, VP Business Development, Watchmaker Genomics    Scott Thurston, Senior Director IT Services, Biodesix, Inc.    Richard Freed, CEO, RheumaGen    Mark Robberson, MBEE, VP Clinical Operations, Sana Health   We thank all who attended and stopped by CBSA’s table to connect.    #CoBioScience #StrongerTogether #InnovationForward #BuildingMomentum #ForgingLifeSciencesFrontier #COHubforHealthImpact  #COLeadsLifeSciences 

We loved working with the very talented team at Wunderdogs on Arpeggio's new website and look! Check out their case study below if you're curious about the inspiration behind our design – they captured the story of our company beautifully. https://lnkd.in/eucYuJhX

We have another amazing announcement, our GPX4 inhibitor combines with a checkpoint inhibitor (anti-PDL1) to dramatically slow the progression of sarcoma in mice! Please stop by Monday April 8th from 1:30-5:00, section number 52, board 10! #AI #Ferroptosis #Transcriptomics #DrugDiscovery #SarcomaResearch

We are excited to present our NRF2 degrader at #AACR2024! This amazing small molecule leads to regression of aggressive lung adenocarcinoma tumors in vivo and was discovered with our AI + Transcriptomics platform. If you are available, please stop by Monday April 8th from 1:30-5:00, section number 52, board 15! #AI #TranscriptionFactors #DrugDiscovery #CancerResearch

Strong Arpeggio representation at SLAS (Society for Laboratory Automation and Screening)with Tim Read and Casey Pham both presenting today in collaboration with Beckman Coulter Life Sciences and Biosero 👏 Be sure to connect with our team if you're there!

✨ Tutorial today! ✨ We'll be serving lunch, updates on #GreenButtonGo, and 3x stories from #scientists making big strides in #labautomation this year. Room 1️⃣0️⃣2️⃣🅱️ Empowering the Full Spectrum of Integrated Lab Automation with Green Button Go 📅 Monday, February 5th, 2024 🕛 12 PM - 1 PM 🏫 Room 102B 👋 Speakers >> Rob Harkness from #Biosero >> Katharine Heeringa from #ScribeTx >> Casey Pham from #Arpeggio >> Erik Snow from #Cellino #SLAS2024 #labautomation #laborchestration #robotics SLAS (Society for Laboratory Automation and Screening)

From academic institutions that are filling major gaps in the mechanistic understanding of MCTO, to industry partners building cell lines and iPSCs (Artisan Bio), studying the over-expression of proteins caused by mutated MafB (SomaLogic), and running transcriptomics studies and high throughput screens on engineered cells (Arpeggio Biosciences), we are learning more each day. Join us in celebrating the season of giving through funding further research being performed by our collaborators at Boston Children's Hospital and Harvard University. Any donation amount, small or large, helps tremendously. To learn more about our grants and collaborations, visit: https://lnkd.in/gPkCrWY5

As we count down to CBSA’s 20th Annual Awards Celebration presented by AGC Biologics, we’re highlighting all the companies that are finalists for our Company of the Year and Rising Star of the Year sponsored by WTW awards. Meet Arpeggio Biosciences, a company uniquely approaching drug discovery by using AI and next-gen RNA sequencing. They are applying high-throughput transcriptomics to match drugs to a disease based not just on a single target, but the biological network as a whole. Congratulations on being honored as a Rising Star of the Year finalist! Space is limited! Secure your spot or join our event waitlist today: https://lnkd.in/gUa4tjxx #CoBioScience #StrongerTogether #InnovationForward #BuildingMomentum #ForgingLifeSciencesFrontier

We are thrilled to be selected by the Colorado BioScience Association as a finalist for the Rising Star of the Year Award! This is a great tribute to the people of Arpeggio and the progress we've made as a team. Together, we are changing the way we discover drugs, and we will continue to make headway toward our goal of developing therapies for diseases driven by transcription factors.